Mielke, Stephan

Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Schuster, S. J., Bishop, M. R., Tam, C. S., Waller, E. K., Borchmann, P., McGuirk, J. P., Jäger, U., Jaglowski, S., Andreadis, C., Westin, J. R., et al. (2019) · New England Journal of Medicine

CAR-T cell therapy researchLymphoma Diagnosis and Treatment

Cited by 4,112

Deficient CD4+ CD25+ FOXP3+ T regulatory cells in acquired aplastic anemia

Solomou, E. E., Rezvani, K., Mielke, S., Malide, D., Keyvanfar, K., Visconte, V., Kajigaya, S., Barrett, A. J., & Young, N. S. (2007) · Blood

T-cell and B-cell ImmunologyBlood disorders and treatments

Cited by 225

New perspectives on the use of mTOR inhibitors in allogeneic haematopoietic stem cell transplantation and graft‐versus‐host disease

Lutz, M., & Mielke, S. (2016) · British Journal of Clinical Pharmacology

Hematopoietic Stem Cell TransplantationRenal Transplantation Outcomes and Treatments

Cited by 32

Allogeneic hematopoietic cell transplantation in patients with chronic phase chronic myeloid leukemia in the era of third generation tyrosine kinase inhibitors: A retrospective study by the chronic malignancies working party of the EBMT

Chalandon, Y., Sbianchi, G., Gras, L., Koster, L., Apperley, J., Byrne, J., Salmenniemi, U., Sengeloev, H., Aljurf, M., Helbig, G., et al. (2023) · American Journal of Hematology

Chronic Myeloid Leukemia TreatmentsHematopoietic Stem Cell Transplantation

Cited by 24